Jefferies Downgrades BridgeBio Pharma to Hold, Raises Price Target to $33
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Eun Yang has downgraded BridgeBio Pharma (NASDAQ:BBIO) from Buy to Hold, while raising the price target from $24 to $33.
July 18, 2023 | 8:46 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Jefferies has downgraded BridgeBio Pharma and raised its price target. This could lead to mixed market reactions.
The downgrade from Buy to Hold suggests that the analyst sees limited upside potential in the short term. However, the raised price target indicates an expectation of long-term growth. This could lead to mixed market reactions in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100